Physician profile
Frederick E Leickly
NPI 1679682710
$981.02
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $366 · 2020: $77.13 · 2021: $363 · 2022: $175.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $303.82 | 2019-2021 | |
| Aimmune Therapeutics, INC. | $209.59 | 2021-2022 | |
| Csl Behring | $91.09 | 2019-2021 | |
| Biocryst US Sales Co., LLC | $86.89 | 2021 | |
| Grifols USA, LLC | $81.21 | 2021 | |
| Novartis Pharmaceuticals Corporation | $50.00 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $37.87 | 2020-2021 | |
| Pfizer INC. | $33.66 | 2019 | |
| Covis Pharma Gmbh | $23.34 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.87 | 2021 | |
| Genentech USA, INC. | $14.26 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $13.99 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $13.43 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frederick Leickly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.